> Detailanzeige

Basset, Marco; Hummedah, Kamal; Kimmich, Christoph; Veelken, Kaya; Dittrich, Tobias; Brandelik, Simone; Kreuter, Michael; Hassel, Jessica; Bosch, Nikolaus; Stuhlmann‐Laeisz, Christiane; Blank, Norbert; Müller‐Tidow, Carsten; Röcken, Christoph; Hegenbart, Ute; Schönland, Stefan

Localized immunoglobulin light chain amyloidosis: Novel insights including prognostic factors for local progression

Literatur-
verwaltung

Zur
Merkliste

Lösche von
Merkliste

Per Whatsapp teilen

Schließen

Merkliste



Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
  • Medientyp: E-Artikel
  • Titel: Localized immunoglobulin light chain amyloidosis: Novel insights including prognostic factors for local progression
  • Beteiligte: Basset, Marco; Hummedah, Kamal; Kimmich, Christoph; Veelken, Kaya; Dittrich, Tobias; Brandelik, Simone; Kreuter, Michael; Hassel, Jessica; Bosch, Nikolaus; Stuhlmann‐Laeisz, Christiane; Blank, Norbert; Müller‐Tidow, Carsten; Röcken, Christoph; Hegenbart, Ute; Schönland, Stefan
  • Erschienen: Wiley, 2020
  • Erschienen in: American Journal of Hematology
  • Sprache: Englisch
  • DOI: 10.1002/ajh.25915
  • ISSN: 0361-8609; 1096-8652
  • Entstehung:
  • Anmerkungen:
  • Beschreibung: <jats:title>Abstract</jats:title><jats:p>In localized light chain amyloidosis (locAL), amyloidogenic light chains (aLC) are produced and deposited locally by a B‐cell clone. We present 293 patients with immunohistochemically confirmed locAL. Lung (nodular pulmonary) with 63 patients was the most involved organ. The aLC was λ in 217 cases (κ:λ ratio 1:3). A local B‐cell clone was identified in 30% of cases. Sixty‐one (21%) had a concomitant autoimmune disorder (cAD). A monoclonal component (MC) were present in 101 (34%) patients and were more frequent in subjects with cAD (51% vs 34%; <jats:italic>P</jats:italic> = .03). Cigarette smoking was more prevalent in lung locAL (54% vs 37%; <jats:italic>P</jats:italic> = .018). After a median follow‐up of 44 months, 16 patients died and 5‐ and 10‐years locAL progression‐free survival (PFS) were 62% and 44%. Interestingly, locAL‐PFS was shorter among patients with an identified clonal infiltrate at amyloid deposition site (40 vs 109 months; <jats:italic>P</jats:italic> = .02) and multinuclear giant cells and/or an inflammatory infiltrate resulted in longer locAL‐PFS in lung involvement (65 vs 42 months; <jats:italic>P</jats:italic> = .01). However, no differences in locAL PFS were observed in patients with cAD, a MC and involved organ site. Treatment was administered in 163 (54%) patients and was surgical in 135 (46%). Median locAL‐PFS after first treatment was 56 months. Responders had longer locAL‐PFS (78 vs 17 months; <jats:italic>P</jats:italic> &lt; .001). Three patients with lung locAL and a MC were diagnosed as systemic AL amyloidosis at follow‐up. In summary, locAL pathogenesis seems to be heterogeneous and the clonal infiltrate leads local progression.</jats:p>
  • Zugangsstatus: Freier Zugang